Summary: Researchers unmasked an alternative biological pathway explaining how GLP-1 receptor agonist medications alleviate psychiatric symptoms. The investigation utilized mouse models of chronic stress to track the psychiatric footprint of the weight-loss and diabetes drug liraglutide.
The research team discovered that instead of acting directly on neural receptors in the brain, the drug accumulates in the intestine. There, it triggers a massive proliferation of the gut microbe Lactobacillus delbrueckii. This strain synthesizes a crucial molecular precursor that the body converts into the endocannabinoid 2-arachidonoylglycerol (2-AG), which successfully down-regulates hyperactivation in stress-related brain regions to neutralize depressive behavior.
Key Facts
- Challenging the Brain-Centric Model: Clinical trials have long yielded contradictory data regarding GLP-1 drugs, with some showing antidepressant qualities and others hinting at mood liabilities. The prevailing scientific consensus assumed these outcomes stemmed from the drugs crossing the blood-brain barrier to hit central nervous system receptors. This study completely upends that model.
- Intestinal Accumulation Over Brain Penetration: Using mouse models, the research team demonstrated that systemically administered liraglutide gathers predominantly within the tissues of the intestine rather than accumulating in the brain.
- The Receptor Knockout Proof: To isolate the mechanical pathway, neuroscientists deployed genetically modified mice with their GLP-1 receptors entirely knocked out. Strikingly, liraglutide retained its full antidepressant and anti-anxiety efficacy in these mice, proving that the psychiatric benefits do not require direct brain-receptor engagement.
- The Antibiotic Elimination Effect: When the investigators cleared the mice’s gut microbiomes using broad-spectrum antibiotics, the antidepressant effects of liraglutide completely vanished. This confirmed that the drug’s mood-elevating properties are entirely dependent on the presence of living gut microorganisms.
- The Lactobacillus delbrueckii Surge: Fecal metagenomic sequencing unmasked that Lactobacillus delbrueckii was the single most significantly increased microbial species following liraglutide treatment. Its population abundance directly matched the scale of behavioral and mood improvements.
- The 2-AG Endocannabinoid Pipeline: L. delbrueckii was shown to produce high volumes of diacylglycerol—a precursor lipid that the host organism converts into the native endocannabinoid 2-arachidonoylglycerol (2-AG). Elevated 2-AG acts as a metabolic handbrake, calming hyperactive, stress-driven neural circuits in the brain.
- A New Horizon for Targeted Probiotics: This discovery introduces powerful clinical avenues for precision medicine, suggesting that clinicians can leverage specific L. delbrueckii probiotic strains to treat comorbid depression in patients managing obesity or type 2 diabetes.
- Recognizing Demographical Limitations: The authors explicitly note that because this mechanistic trial was executed solely in male mouse models, future trials must include female subjects to verify if the same microbiome-endocannabinoid pathway regulates mood across both sexes.
Source: Cell Press
Some people taking GLP-1 drugs for diabetes and obesity experience mental health benefits—particularly, a decrease in symptoms of depression.
In a mouse model study in the Cell Press journal Cell Host & Microbe publishing on June 10, researchers report that these mental health improvements appear to result from changes in the gut microbiome that lead to an abundance of a microbe strain known to have a favorable effect on neurons related to stress.
“Previous clinical and preclinical studies have been contradictory,” says co-corresponding author Yonggui Yuan of Southeast University in Jiangsu, China. “Some studies reported antidepressant effects of GLP-1 agonists, while others suggested increased risk of depression or anxiety. The prevailing model held that these drugs act directly on GLP-1 receptors in the brain, while our study provides evidence for an alternative pathway.”
For this study, the researchers used the weight-loss drug liraglutide, marketed under the brand names Victoza and Saxenda. To determine the drug’s effect on the brain, the team mimicked stress in mouse models. “We observed that when we systemically administered liraglutide to the mice, it accumulated predominantly in the intestine rather than the brain,” says co-corresponding author Bing Han, also of Southeast University.
Using standard behavioral tests, the researchers showed that liraglutide retained its antidepressant activity even in mice with GLP-1 receptors knocked out. This suggested the effects came about through another pathway.
The team then showed that mice whose gut microbiota had been depleted using broad-spectrum antibiotics did not experience liraglutide’s antidepressant effects, pointing to a key role for the microorganisms in the gut.
To identify specific microbial taxa involved, the team studied fecal samples from the mice. Among the microorganisms altered by liraglutide, Lactobacillus delbrueckii was the most significantly increased species. L. delbrueckii produces diacylglycerol—a precursor that is converted into the endocannabinoid 2-arachidonoylglycerol (2-AG). Elevated 2-AG is known to normalize hyperactivation in stress-related brain regions.
“We found that the abundance of L. delbrueckii correlated with behavioral improvements,” says co-corresponding author Honghong Yao, also of Southeast University.
This finding revealed a brain-gut microbiota connection that directly links metabolic drugs such as liraglutide to mood regulation.
The researchers say the finding suggests several potential clinical applications, including treating patients with metabolic conditions such as diabetes and obesity who are also experiencing depression and targeting depression through probiotic intervention.
They also note several limitations to the work, including the fact that it was done in mouse models, not humans, and that the mice were all male. Because depression is different in males and females, it’s important to determine whether the mechanisms are the same in both sexes, says the team.
Funding: This work was supported by grants from the Science and Technology Innovation 2030-Major Project of the Ministry of Science and Technology of China, the National Natural Science Foundation of Distinguished Young Scholars, the National Natural Science Foundation of China, the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, the Major Science and Technology Projects in Jiangsu Province, the Natural Science Foundation Outstanding Youth Fund of Jiangsu Province, the Fundamental Research Funds for the Central Universities, the Jiangsu Province High-Level Hospital Construction Funds of Zhongda Hospital, School of Medicine, Southeast University, and the Nanjing U35 Strong Foundation Program.
Key Questions Answered:
A: By physically restructuring the gut microbiome. While scientists previously assumed GLP-1 drugs had to travel directly to the brain to lift depression, Southeast University researchers proved that liraglutide accumulates in the intestines. Once there, it acts as a biological fertilizer for a helpful gut bacterium called Lactobacillus delbrueckii, triggering a chemical chain reaction that signals the brain from the gut.
A: The link is an endocannabinoid called 2-AG. The study found that Lactobacillus delbrueckii produces a massive supply of a lipid called diacylglycerol. The body naturally converts this lipid into 2-AG, a powerful internal endocannabinoid. When 2-AG levels rise, it travels to stress centers in the brain, acts as a natural stabilizer, and turns down the neural hyperactivity that drives anxiety and depressive behaviors.
A: No, this study was a controlled animal trial specifically mapped in mouse models of stress, and further human clinical trials are required. However, the discovery opens up an exciting breakthrough for precision medicine: it suggests that instead of taking a heavy metabolic drug, patients might eventually be able to treat depression directly using targeted, high-potency probiotics containing Lactobacillus delbrueckii to trigger the same stress-reducing gut-brain pathway.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuropharmacology and depression research news
Author: Julia Grimmett
Source: Cell Press
Contact: Julia Grimmett – Cell Press
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Microbiota-driven gut–brain signaling underlies antidepressant effects of a GLP-1 analog” by Liang Bian, Yang Cai, Yuan Zhang, Ling Shen, Huijuan Wang, Feng Gao, Ningbo Cai, Wenbo Chen, Conghui You, Yurui Yang, Fang Wang, Yonggui Yuan, Bing Han, and Honghong Yao. Cell Host & Microbe
DOI:10.1016/j.chom.2026.05.003
Abstract
Microbiota-driven gut–brain signaling underlies antidepressant effects of a GLP-1 analog
Despite widespread clinical use of glucagon-like peptide-1 receptor (GLP-1R) agonists for metabolic disease, their neuropsychiatric effects remain poorly understood and controversial.
Here, we demonstrate that liraglutide alleviates depression through a gut-brain pathway that operates independently of GLP-1R. Using both pharmacological and genetic approaches, we demonstrated that liraglutide retained antidepressant efficacy in GLP-1R antagonist-Exn9-treated mice or in Glp1r−/− mice, whereas gut microbiota depletion abolished its effects.
Multi-omics analyses revealed that liraglutide increased the abundance of Lactobacillus delbrueckii, which in turn restored the levels of the endocannabinoid 2-arachidonoylglycerol (2-AG).
The elevation of 2-AG mediated the antidepressant effects by normalizing excessive neuronal activity in emotional processing brain regions. Importantly, fecal microbiota transplantation from liraglutide-treated mice or Lactobacillus delbrueckii colonization replicated the antidepressant effects.
These findings uncover a non-canonical mechanism of action for GLP-1 analogs, highlighting a specific microbiota-endocannabinoid metabolic pathway as a potential therapeutic target for depression.
